Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VTB reported for 8 months of 2024 by IFRS

9/27/24 VTBR

Shareholders of TNS Energy Kuban approved dividends

9/26/24 KBSB

Shareholders of Delimobil approved dividends

9/26/24 DELI

Shareholders of Tatneft approved dividends

9/26/24 TATN

Shareholders of Zaymer approved dividends for 6 months 2024

9/26/24 ZAYM

Lukoil develops a network of filling stations in Kazakhstan

9/26/24 LKOH

Bank of Russia against direct investor access to trading

9/26/24 MOEX

Sovcombank became a minority shareholder of Home Bank

9/26/24 SVCB

Shareholders of INARCTICA approved dividends

9/26/24 AQUA

Magnit opened the first stores in the Irkutsk region

9/25/24 MGNT